Priunta 150mg Injection

About

Priunta 150mg Injection, containing Trastuzumab, is a monoclonal antibody specifically designed to target the human epidermal growth factor receptor 2 (HER2) protein. It is indicated for the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. HER2 is a protein that can be overexpressed in certain cancer cells, leading to aggressive tumor growth. Trastuzumab works by binding to the HER2 receptor on the surface of cancer cells, thereby inhibiting cell proliferation and promoting antibody-dependent cell-mediated cytotoxicity (ADCC), which helps the immune system destroy cancer cells.

This medication is administered intravenously and is often used in combination with chemotherapy or as a single agent, depending on the stage and type of cancer. Prior to initiating treatment, patients must undergo HER2 testing to confirm overexpression. A significant concern with Trastuzumab is the risk of cardiac dysfunction, including congestive heart failure, particularly when administered concurrently with or following anthracycline-based chemotherapy. Regular monitoring of cardiac function, typically with echocardiograms or MUGA scans, is essential throughout and after treatment.

Uses

• HER2-positive early breast cancer
• HER2-positive metastatic breast cancer
• HER2-positive metastatic gastric cancer
• HER2-positive gastroesophageal junction adenocarcinoma

Directions For Use

Administered intravenously by a healthcare professional. Dosage and frequency are determined by your doctor based on your body weight and cancer type.

Benefits

• Targets HER2-positive cancer cells specifically
• Improves survival rates in HER2-positive breast cancer
• Reduces risk of cancer recurrence
• Effective in metastatic gastric cancer
• Can be used in combination with chemotherapy
• Offers a personalized treatment approach

Side Effects

• Fever
• Chills
• Nausea
• Diarrhea
• Headache
• Fatigue
• Infusion-related reactions
• Cardiac dysfunction (heart failure)
• Cough
• Rash
• Muscle pain
• Anemia

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to avoid alcohol during cancer treatment.
• Pregnancy - Trastuzumab can cause fetal harm and is contraindicated during pregnancy. Effective contraception must be used.
• Breastfeeding - Breastfeeding is not recommended during Trastuzumab treatment due to potential harm to the infant.
• Liver - Use with caution in patients with severe liver impairment, although no specific dose adjustments are typically required.
• Kidney - No specific dose adjustment is typically required for mild to moderate kidney impairment. Use with caution in severe renal dysfunction.
• Lung - Rare cases of interstitial pneumonitis and pulmonary fibrosis have been reported. Monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.